Mèlanie V Bénard1, Clara M A de Bruijn1,2,3, Aline C Fenneman4,5, Koen Wortelboer5, Judith Zeevenhoven2, Bente Rethans1, Hilde J Herrema5, Tom van Gool6, Max Nieuwdorp5, Marc A Benninga2, Cyriel Y Ponsioen1. 1. Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology Endocrinology Metabolism (AGEM), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. 2. Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Pediatric Gastroenterology, Hepatology and Nutrition, Amsterdam, The Netherlands. 3. Amsterdam Reproduction & Development Research Institute, Amsterdam UMC, Emma Children's Hospital, Amsterdam, The Netherlands. 4. Department of Endocrinology and Metabolism, Amsterdam Gastroenterology Endocrinology Metabolism (AGEM), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. 5. Department of Clinical and Experimental Vascular Medicine, Amsterdam Cardiovascular Sciences (ACS), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. 6. Section Clinical Parasitology, Department of Medical Microbiology, Amsterdam University Medical Centers, Amsterdam Medical Center, Amsterdam, The Netherlands.
Abstract
BACKGROUND: The increasing interest to perform and investigate the efficacy of fecal microbiota transplantation (FMT) has generated an urge for feasible donor screening. We report our experience with stool donor recruitment, screening, follow-up, and associated costs in the context of clinical FMT trials. METHODS: Potential stool donors, aged between 18-65 years, underwent a stepwise screening process starting with an extensive questionnaire followed by feces and blood investigations. When eligible, donors were rescreened for MDROs and SARS-CoV-2 every 60-days, and full rescreening every 4-6 months. The costs to find and retain a stool donor were calculated. RESULTS: From January 2018 to August 2021, 393 potential donors underwent prescreening, of which 202 (51.4%) did not proceed primarily due to loss to follow-up, medication use, or logistic reasons (e.g. COVID-19 measures). 191 potential donors filled in the questionnaire, of which 43 (22.5%) were excluded. The remaining 148 candidates underwent parasitology screening: 91 (61.5%) were excluded, mostly due to Dientamoeba fragilis and/or high amounts of Blastocystis spp. After additional feces investigations 18/57 (31.6%) potential donors were excluded (mainly for presence of Helicobacter Pylori and ESBL-producing organisms). One donor failed serum testing. Overall, 38 out of 393 (10%) potential donors were enrolled. The median participation time of active stool donors was 13 months. To recruit 38 stool donors, €64.112 was spent. CONCLUSION: Recruitment of stool donors for FMT is challenging. In our Dutch cohort, failed eligibility of potential donors was often caused by the presence of the protozoa Dientamoeba fragilis and Blastocystis spp.. The exclusion of potential donors that carry these protozoa, especially Blastocystis spp., is questionable and deserves reconsideration. High-quality donor screening is associated with substantial costs.
BACKGROUND: The increasing interest to perform and investigate the efficacy of fecal microbiota transplantation (FMT) has generated an urge for feasible donor screening. We report our experience with stool donor recruitment, screening, follow-up, and associated costs in the context of clinical FMT trials. METHODS: Potential stool donors, aged between 18-65 years, underwent a stepwise screening process starting with an extensive questionnaire followed by feces and blood investigations. When eligible, donors were rescreened for MDROs and SARS-CoV-2 every 60-days, and full rescreening every 4-6 months. The costs to find and retain a stool donor were calculated. RESULTS: From January 2018 to August 2021, 393 potential donors underwent prescreening, of which 202 (51.4%) did not proceed primarily due to loss to follow-up, medication use, or logistic reasons (e.g. COVID-19 measures). 191 potential donors filled in the questionnaire, of which 43 (22.5%) were excluded. The remaining 148 candidates underwent parasitology screening: 91 (61.5%) were excluded, mostly due to Dientamoeba fragilis and/or high amounts of Blastocystis spp. After additional feces investigations 18/57 (31.6%) potential donors were excluded (mainly for presence of Helicobacter Pylori and ESBL-producing organisms). One donor failed serum testing. Overall, 38 out of 393 (10%) potential donors were enrolled. The median participation time of active stool donors was 13 months. To recruit 38 stool donors, €64.112 was spent. CONCLUSION: Recruitment of stool donors for FMT is challenging. In our Dutch cohort, failed eligibility of potential donors was often caused by the presence of the protozoa Dientamoeba fragilis and Blastocystis spp.. The exclusion of potential donors that carry these protozoa, especially Blastocystis spp., is questionable and deserves reconsideration. High-quality donor screening is associated with substantial costs.
Authors: Noortje G Rossen; Susana Fuentes; Mirjam J van der Spek; Jan G Tijssen; Jorn H A Hartman; Ann Duflou; Mark Löwenberg; Gijs R van den Brink; Elisabeth M H Mathus-Vliegen; Willem M de Vos; Erwin G Zoetendal; Geert R D'Haens; Cyriel Y Ponsioen Journal: Gastroenterology Date: 2015-03-30 Impact factor: 22.682
Authors: Sudarshan Paramsothy; Thomas J Borody; Enmoore Lin; Sarah Finlayson; Alissa J Walsh; Douglas Samuel; Johan van den Bogaerde; Rupert W L Leong; Susan Connor; Watson Ng; Hazel M Mitchell; Nadeem Kaakoush; Michael A Kamm Journal: Inflamm Bowel Dis Date: 2015-07 Impact factor: 5.325
Authors: N G Rossen; A Bart; N Verhaar; E van Nood; R Kootte; P F de Groot; G R D'Haens; C Y Ponsioen; T van Gool Journal: Eur J Clin Microbiol Infect Dis Date: 2015-02-14 Impact factor: 3.267
Authors: Giovanni Cammarota; Gianluca Ianiro; Colleen R Kelly; Benjamin H Mullish; Jessica R Allegretti; Zain Kassam; Lorenza Putignani; Monika Fischer; Josbert J Keller; Samuel Paul Costello; Harry Sokol; Patrizia Kump; Reetta Satokari; Stacy A Kahn; Dina Kao; Perttu Arkkila; Ed J Kuijper; Maria J Gt Vehreschild; Cristina Pintus; Loris Lopetuso; Luca Masucci; Franco Scaldaferri; E M Terveer; Max Nieuwdorp; Antonio López-Sanromán; Juozas Kupcinskas; Ailsa Hart; Herbert Tilg; Antonio Gasbarrini Journal: Gut Date: 2019-09-28 Impact factor: 23.059
Authors: Chiazotam Ekekezie; Bryce K Perler; Anna Wexler; Catherine Duff; Christian John Lillis; Colleen R Kelly Journal: Am J Gastroenterol Date: 2020-04 Impact factor: 12.045